Company Analysis
Sign in

Quoin Pharmaceuticals, Ltd. (QNRX)

Nasdaq: QNRX · Pharmaceutical Preparations · filing with the SEC since 2016
Full chart Alerts Compare
Grade4.8
◀ Past 5.0● Present 3.4▶ Future 6.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Report filedMar 26, 2026Mar 13, 2025Mar 14, 2024Mar 15, 2023Apr 14, 2022Mar 29, 2021Apr 3, 2020Mar 18, 2019
Revenue····000·
Research and development9,802,8073,602,6323,307,9872,672,8361,562,927244,15545,650·
Selling, general and administrative6,487,9095,925,8336,070,5176,584,8684,499,9231,425,8551,514,751·
Total costs and expenses16,290,7169,528,4659,378,5049,257,7046,062,8501,670,0101,560,401·
Interest expense····1,090,40947,021··
Interest and investment income482,081558,491·95,745····
Total non-operating income (expense)486,061565,993691,931-123,792-15,399,738-425,354··
Income before income taxes-15,804,655-8,962,472······
Net income including non-controlling interests-15,804,655-8,962,472-8,686,573-9,381,496-21,462,588-2,095,364-1,560,401·
Net income-15,804,655-8,962,472-8,686,573-9,381,496-21,462,588-2,095,364-1,560,401·
Net income to common shareholders··-8,686,573-9,446,762-21,462,588···
Earnings per share, basic····-0.01-0.70-0.52·
Earnings per share, diluted····-0.01-0.70-0.52·
Weighted average shares, basic····1,584,905,5941,201,460,8001,201,460,800·
Weighted average shares, diluted····1,584,906b1,201,461b1,201,461b·
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:OperatingCostsAndExpenses
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterestAndDividend
us-gaap:InterestIncomeOther
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton QNRX · research, not advice